Effect of simvastatin on the lipid profile of hemodialysis patients

Nishikawa, Osamu; Mune, Masatoshi; Miyano, Motoshige; Nishide, Takahiro; Nishide, Iwao; Maeda, Akinori; Kimura, Keigo; Takahashi, Toshio; Kishino, Masanori; Tone, Yoshinori; Otani, Haruhisa; Ogawa, Akio; Maeda, Toshio; Yukawa, Susumu

doi:10.1046/j.1523-1755.1999.07157.x

Cited by 40 publications

(19 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yet, as already mentioned for pravastatin, the majority of the published studies with the use of simvastatin did not show any favorable effect on LDL subclasses or size: in patients with primary hypercholesterolaemia [38], with combined [37,41] or familial combined hyperlipidemia [40], with familial hypercholesterolemia [39,44,46], with type II [35] or IIb dyslipidemia [34,42], with type 2 diabetes [44], in hemodialysis [43,45], with low HDL-cholesterol levels and increased concentrations of LDL-cholesterol [36], total cholesterol [43] or triglycerides [45].…”

Section: Simvastatinmentioning

confidence: 88%

“…Simvastatin therapy showed a wide range of responses, including significant [27][28][29][30], moderate [31][32][33] and no effects [34][35][36][37][38][39][40][41][42][43][44][45][46] on LDL subclasses and size (Table 1).…”

Section: Simvastatinmentioning

confidence: 99%

“…Many studies also considered higher-risk populations, such as those with CAD [14,15,29,33,36,77], type II diabetes [25,44,50,52,57,58,62,66,74,75,77], metabolic syndrome [28], end-stage renal disease [43,45,63,66,78,79] or postmenopausal women [31,32,49,51]. The methodology used to assess LDL peak particle size and subclasses varied: the majority of the studies used gradient gel electrophoresis (GGE) or density gradient ultracentrifugation (DGUC), but other authors used ultracentrifugation (UC), nuclear magnetic resonance (NMR) or the Lipoprint system, a commercially available method of plasma lipoprotein separation by GGE.…”

Section: Clinical and Laboratory Factors Influencing Ldl Size Modulatmentioning

confidence: 99%

See 2 more Smart Citations

The Clinical Relevance of Low-Density-Lipoproteins Size Modulation by Statins

Rizzo

Berneis

2006

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

The predominance of small, dense low density lipoproteins (LDL) has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III; in fact, LDL size seems to be an important predictor of cardiovascular events and progression of coronary heart disease. Several studies have also shown that the therapeutical modulation of LDL size is of great benefit in reducing the risk of cardiovascular events. Hypolipidemic treatment is able to alter LDL subclass distribution and statins are currently the most widely used lipid-lowering agents. Statins are potent inhibitors of hydroxy-methyl-glutaryl-coenzyme A reductase, the rate-limiting enzyme in hepatic cholesterol synthesis and are the main drugs of choice for the treatment of elevated plasma LDL cholesterol concentrations. Statins potentially lower all LDL subclasses (e.g., large, medium and small particles); thus, their net effect on LDL subclasses or size is often only moderate. However, a strong variation has been noticed among the different agents: analyses of all published studies suggest a very limited role of pravastatin and simvastatin in modifying LDL size and their subclasses, while fluvastatin and atorvastatin seem to be much more effective agents. Finally, rosuvastatin, the latest statin molecule introduced in the market, seems to be promising in altering LDL subclasses towards less atherogenic particles.

show abstract

Section: Simvastatinmentioning

confidence: 88%

Section: Simvastatinmentioning

confidence: 99%

Section: Clinical and Laboratory Factors Influencing Ldl Size Modulatmentioning

confidence: 99%

See 1 more Smart Citation

The Clinical Relevance of Low-Density-Lipoproteins Size Modulation by Statins

Rizzo

Berneis

2006

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

show abstract

“…One of the well-documented effects of statin treatment of hypercholesterolemic patients is reduction of apoE levels in plasma [18][19][20][21] , while statin effects on CSF apoE levels remain unclear [22] . Statins penetrate the blood-brain barrier (BBB) with different efficiency, depending on their lipophilicity [23,24] .…”

Section: Introductionmentioning

confidence: 99%

Statins of Different Brain Penetrability Differentially Affect CSF PLTP Activity

Vuletic

Riekse

Marcovina

et al. 2006

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Background/Aims: Phospholipid transfer protein (PLTP) and apolipoprotein E (apoE) are key proteins involved in lipoprotein metabolism in the peripheral circulation and in the brain. Several epidemiological studies suggested that use of 3-hydroxyl-3-methylglutaryl-coenzyme A reductase inhibitors (statins) reduces risk of Alzheimer’s disease (AD). However, the effects of statins of differing blood-brain barrier (BBB) penetrability on brain-derived molecules in cognitively normal individuals are largely unknown. Methods: To assess the effect of statins on these indices as a function of BBB penetration, cerebrospinal fluid (CSF) and plasma PLTP activity and apoE concentration were measured in cognitively intact, modestly hypercholesterolemic adults randomly allocated to treatment with either pravastatin, which does not penetrate BBB (80 mg/day, n = 13), or simvastatin, which penetrates BBB (40 mg/day, n = 10). Results: Simvastatin significantly increased CSF PLTP activity (p = 0.005). In contrast, pravastatin had no such effect. In the pravastatin-treated group, CSF apoE concentration decreased significantly (p = 0.026), while the simvastatin-treated group showed a tendency towards lower CSF apoE levels, with CSF apoE concentration lowered in 8 of 10 subjects. Conclusion: Our data indicate that statins differentially affect two key lipid transfer proteins in the brain, and that effect on PLTP activity depends on statin BBB penetrability.

show abstract

“…All statins available today are excreted through bile. Effective and safe use in Japanese dialysis patients has been reported for pravastatin (88), simvastatin (89), fluvastatin (90), and atorvastatin (91). These statins reduce plasma LDL cholesterol by approximately 25-40%.…”

Section: The Nkf K/doqi Has Published the Clinical Practice Guidelinementioning

confidence: 99%

Chronic Kidney Disease as a Metabolic Syndrome with Malnutrition-Need for Strict Control of Risk Factors

Shoji

Nishizawà

2005

Intern. Med.

View full text Add to dashboard Cite

Effect of simvastatin on the lipid profile of hemodialysis patients

Abstract: Effect of simvastatin on the lipid profile of hemodialysis patients.hibit dyslipidemia, which is thought to be one of the Background. Simvastatin, a 3-hydroxy 3-methylglutaryl co-

Cited by 40 publications

References 9 publications

The Clinical Relevance of Low-Density-Lipoproteins Size Modulation by Statins

The Clinical Relevance of Low-Density-Lipoproteins Size Modulation by Statins

Statins of Different Brain Penetrability Differentially Affect CSF PLTP Activity

Chronic Kidney Disease as a Metabolic Syndrome with Malnutrition-Need for Strict Control of Risk Factors

Contact Info

Product

Resources

About